News Articles and Montana BioScience Alliance Newsletters

MONTANA BIOSCIENCE ENTERPRISES IN THE NEWS

Last year, the World Trade Organization (WTO) proposed that biotechnology companies, including some in Montana, be required to give their formulas for COVID-19 vaccines to countries that aren’t as advanced as the U.S. in developing these technologies. The Biden administration has supported this proposal, but we have deep concerns about it.

The immuno-oncology market has grown at a compound rate of 10%, from $57 billion to $69 billion in 2021. It is expected to reach around $98 billion by 2025. This is a highly competitive market, so companies in this sector have to innovate rapidly by creating novel drugs and therapies. Montana’s Inimmune recently made the top-20 list.

A Montana State University undergraduate has been admitted to a prestigious European graduate program where she will advance her research in disease prevention and other applications of the growing field of bioinformatics.

Beginning with cannabis, the Missoula, MT based company is creating a self-contained and portable product that can detect impairment in real-time. The product will be sold to law enforcement agencies, and businesses with safety-critical employees.

Tonix Pharmaceuticals
|
March 9, 2022

Tonix Pharmaceuticals will collaborate with Massachusetts General Hospital to further develop a humanized monoclonal antibody, TNX-1500, to prevent organ transplant rejection, specifically in kidney transplants.

ARTICLES OF INTEREST

Bio event draws about 3,000 companies to the San Diego Convention Center to take stock of the latest trends and research.

Four-time gold medalist and seven-time Grand Slam singles champion Venus Williams will discuss her groundbreaking career, business success, and prioritizing health in a conversation moderated by Emmy-nominated sports reporter Erin Andrews at the BIO International Convention June 13-16, 2022, in San Diego. Both women have faced their own health challenges, becoming advocates for increased awareness and better outcomes for all.

New York Times
|
May 21, 2022

As the pandemic enters its third year, long Covid has emerged as an increasingly important concern. And many people are wondering whether getting a Covid shot can reduce their chances of developing long-term symptoms.

Congress has returned to Capitol Hill, and among the most important unfinished business on its agenda is agreeing to a new package to fight COVID-19 by funding second-generation vaccine research. When Congress left town, there was cautious optimism that a deal was close.

Rocky Mountain Life Sciences Investor and Partnering Conference
|
April 7, 2022

Thirty regional companies will be selected to present at the Rocky Mountain Life Sciences Investor & Partnering Conference. Companies seeking seed, early-stage, late-stage funding in the medical device, diagnostic, biotech, pharmaceutical, and digital health sectors are encouraged to apply.

NEWSLETTER

Newsletter
|
May 6, 2022
Newsletter
|
February 25, 2022

View the Winter II 2022 now!